AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Mar 17, 2015

AbbVie's Dermatology Leadership Showcased with HUMIRA® (adalimumab) Data at American Academy of Dermatology 2015 Annual Meeting

NORTH CHICAGO, Ill., March 17, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from 22 abstracts on HUMIRA® (adalimumab) and dermatological diseases will be presented at the upcoming 73rd Annual Meeting of the American Academy of Dermatology (AAD), March 20 – 24, in San Francisco. AbbVie's presence at AAD demonstrates the company's commitment to the field of dermatology, which is grounded in HUMIRA. HUMIRA is one of the most comprehensively studied biologics available, and is distinguished by 12 years of physician and patient experience in dermatology.

Mar 06, 2015

AbbVie to Present at Barclays Global Health Care Conference

NORTH CHICAGO, Ill., March 6, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Health Care Conference on Thursday, March 12, 2015. Richard A. Gonzalez, chairman and chief executive officer, will participate in a question and answer session at 8:30 a.m. Central time.

Mar 04, 2015

AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise

NORTH CHICAGO, Ill. and SUNNYVALE, Calif., March 4, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Pharmacyclics (NASDAQ: PCYC) today announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its flagship asset  Imbruvica® (ibrutinib), a highly effective treatment for hematologic malignancies.   The acquisition accelerates AbbVie's clinical and commercial presence in oncology, strengthening its already robust pipeline, and establishing its strong leadership position in hematological oncology – an attractive and rapidly growing market, now approaching $24 billion globally.  The acquisition adds to AbbVie's already comprehensive pipeline and strong growth prospects.

Feb 27, 2015

AbbVie's HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Children and Adolescents With Severe Chronic Plaque Psoriasis

– Marketing Authorization Decision Expected from the European Commission in the Second Quarter –

Feb 26, 2015

AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting

NORTH CHICAGO, Ill., Feb. 26, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 15 abstracts of studies in its neuroscience and oncology development programs have been accepted for presentation during the 67th American Academy of Neurology annual meeting in Washington, D.C., from April 18-25. The accepted abstracts feature results from studies evaluating AbbVie's FDA-approved product, DUOPA, in addition to investigational treatments in AbbVie's pipeline. Presentations will include Phase 1 results from a study of ABT-414 in patients with glioblastoma multiforme, Phase 3 data for ZINBRYTA™ (daclizumab high-yield process), which is being developed jointly with Biogen Idec, in relapsing remitting multiple sclerosis, and results from a study of DUOPA (carbidopa and levodopa) enteral suspension in advanced Parkinson's disease.

Feb 25, 2015

AbbVie to Present at Cowen 35th Annual Health Care Conference

NORTH CHICAGO, Ill., Feb. 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen 35th Annual Health Care Conference on Wednesday, March 4, 2015. Bill Chase, executive vice president and chief financial officer, will make a presentation on the company and participate in a question and answer session at 9 a.m. Central time.

Feb 23, 2015

Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) Published Online in JAMA; Sub-analyses to be Presented at the Annual Confere

NORTH CHICAGO, Ill., Feb. 23, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that results from part one of the Phase 2 portion of its Phase2/3 open-label study, TURQUOISE-I, in genotype 1 chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection were published online in The Journal of the American Medical Association (JAMA). Additional sub-analyses also will be presented in both oral and poster presentations on Feb. 26, at the Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Wash.

Feb 11, 2015

AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C

NORTH CHICAGO, Ill., Feb. 11, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily. The submission is for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection.

Jan 30, 2015

AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results

NORTH CHICAGO, Ill., Jan. 30, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2014.